The philosophy
Ikigai
THe SYMBOL
- You and NattoPharma
- Science and Partnership
the tagline
what's staying the same
- Our purpose-led commitment to provide you with increasingly better tools, knowledge, marketing, and product support, as if we were your own personal “back-office”.
- The only company to provide crucial clinical evidence to support the health claims you can confidently make to improve consumers' health.
- Supplying of the most comprehensive Vitamin K2 portfolio – both natural fermented and nature-identical synthesis in various dilutions and solubilities.
- Personalized support paired with portfolio flexibility to bring your product ideas to life.
SCROLL the journey
NattoPharma Develops the Category and Brings Vitamin K2 to the Masses
K2 Origins and Discovery
Japanese first consume fermented soybeans, called “natto”.
Shared by Henrik Dam (DK) for discovery of vitamin K and Edward Doisy (US) for discovery of its chemical structure.
Dr. Weston Price identifies fat-soluble vitamin missing in modern diets that is connected to bone and teeth degeneration.
Inspired by Natto’s Link to Bone Health
Determined to Bring K2 to Humans Globally
they knew they had to find a way to move from observational to clinical proof.
Aligned with Univ. Maastricht Discovers K2
mechanism, elucidating K2’s benefits for bone and cardiovascular health as we know it today.
NattoPharma ASA Founded with Mission
to bring K2 to the masses and provide clinical proof of its health benefits.
The First K2 Ingredient
MenaQ7 Bone Study in Healthy
MenaQ7 K Deficiency Study
MenaQ7 Dose-Finding Safety Study
publishes in the Brit J Nutr.
Breakthrough 3-Year MenaQ7 Bone
MenaQ7 Study Examining K2
status in children and adults publishes in Food & Function.
MenaQ7 Study Exploring K2
supplementation impact on OAC therapy publishes in Thromb and Haemo.
MenaQ7 Dose-Finding Study
in haemodialysis patients publishes in Nephr Dial Trans.
US Patent Application Expanded
K2 & Omega-3 Canadian Patent
awarded to NattoPharma
Breakthrough MenaQ7 3-Year Cardio
MenaQ7 PURE is Best New Ingredient
at Natural Products Expo West; granted Novel Food Approval from EFSA
Drug Master File completed
2.9M Euro Grant Awarded
to NattoPharma Research Network.
MenaQ7 is Non-GMO Verified
Awarded New Patent
allowing claims MK-7 reduces incidence of age-related hardening of arteries.
MenaQ7 Study Confirms
effective delivery via yogurt.
MenaQ7 Inflammation Study
publishes in J Med Food.
Horizon 2020 EU Research Grant
4M Euro Research Grant
awarded to NattoPharma Research Network.
Norwegian Research Council Grant
awarded to NattoPharma.
MenaQ7 Natto MK-7; Full Spectrum K2
launches.
MenaQ7 1-Year Cardio Study
K2 RDI program
spearheaded by NattoPharma.
K2 RDI Effort:
K2 RDI effort:
new paper defines roles of Vitamins K1 and K2.
NattoPharma Advances Cardio Argument
with grant-funded paper.
UK Consumer Outreach Program
features MenaQ7 products; results in increased awareness.
Univ. Maastricht Research
MenaQ7 1-Year Cardio Study
in men and women publishes in Vasc Dis Thera.
K2 RDI effort:
paper by NattoPharma research partner identifies need for K2 RDI.
COVID-19 and Vitamin K
status connection first identified in preliminary research.
New US Office / Warehouse
Intent To Acquire Nattopharma
by Compagnie Des Levures Lesaffre.
MEET THE TEAM
Management & Board of Directors
MANAGEMENT
Kjetil Ramsøy
kjetil.ramsoy@nattopharma.com
Robert Schrama
robert.schrama@nattopharma.com
William Sommer
william.sommer@nattopharma.com
Laura Bakker
laura.bakker@nattopharma.com
Andrew Green
VP Global Marketing & Communications
andrew.green@nattopharma.com
Elise Kaiser
elise.kaiser@nattopharma.com
Rudi de Man
rudi.deman@nattopharma.com
Eric Anderson
eric.anderson@nattopharma.com
board of directors
Frode Bohan started his career within the industry in 1991 and founded the original NattoPharma Ltd (later NattoPharma ASA) in 2004, where he has been a significant shareholder from the incorporation. After two decades-long track record of founding and establishing prosperous companies, Mr. Bohan serves now as the Executive Chairman of NattoPharma. Mr. Bohan has studied marketing and computer science and based on the experience from building the MenaQ7 brand, he founded NoLabel and NutriCon, which are the world leading nutraceutical and pharmaceutical communications companies. Moreover, Mr. Bohan is a substantial Shareholder of Eqology ASA, and the chairman of the Board of directors at ImmunoPharma AS.
Sjur Thorsheim holds a law degree from the University of Oslo. For the last 20 years he has been a professional investor, investing in non-listed companies within industries such as aerospace, real estate, advertising, and security.
Annette Elmqvist, Pharmacist from Uppsala University. Started her career at the Medical Product agency and over 20 years within former Pharmacia as Qualified person/Production manager, Director of Operation at SBL vaccine and CEO at Unitech Biopharma. Current position is VP Quality Assurance at Scandinavian Biopharma AB. The broad experience within pharmaceutical industry especially within quality and production processes give her the mission to support companies to develop new products.
Mr. Halldén is today working chairman of Life Science Sweden AB, a long-time shareholder in NattoPharma and a valuable contributor to the development of the company. The last year he also held the position as a member of the Election Committee. Halldén has a long track record from international finance.
Katarzyna Maresz is a master’s graduate at the Jagiellonian University, Pharmacy Faculty (specialization: Medical Analytics, 1998). Holds a PhD in Biological Sciences at the Medical Faculty of the Jagiellonian University (2002). Held her practice at the Laboratory of Cellular and Molecular Immunology, Blood Research Institute, in Milwaukee, WI, USA (2003-2006). She is a post-doctoral fellow within the Marie-Curie Programme at the Department of Microbiology. Currently she is a scientific staff member at the Department of Biochemistry, Biophysics and Biotechnology at the Jagiellonian University as a part of a research project financed by the European Union.
